NGM Biopharmaceuticals' (NGM) average rating among analysts is a buy, with an average price target of $26. Price: 14.45, Change: +0.60, Percent Change:...
NGM Biopharmaceuticals (NGM) on Wednesday said it will present new data from a phase 1b study of NGM313 at the 79th Scientific Sessions of the American...
NGM Biopharmaceuticals' (NGM) net loss widened to $1.21 per share in Q1 from $0.64 per share a year earlier, even as revenue rose to $25.55 million from...
NGM Biopharmaceuticals' (NGM) average rating among analysts is a buy, with an average price target of $25. Price: 15.90, Change: +0.21, Percent Change:...
| Address | 333 Oyster Point Boulevard South San Francisco, California 94080-7014 |
| Phone | +1.650.243.5555 |
| Number of Employees | N/A |
| Recent SEC Filing | 08/12/2019 8-K |
| Executive Chairman & Secretary | William J. Rieflin |
| Chief Executive & Financial Officer, Director | David J. Woodhouse |
| President & Chief Operating Officer | Aetna Wun Trombley |
| Director & Chief Scientific Officer | Jin-Long Chen |
| Price Open | $15.81 |
| Previous Close | $16.10 |
| 52 Week Range | $12.00 - 19.27 |
| Market Capitalization | $1.1 B |
| Shares Outstanding | 66.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/11/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.25 |
| Beta vs. S&P 500 | N/A |
| Revenue | $108.7 M |
| Net Profit Margin | -31.31% |
| Return on Equity | -12.21% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
